1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Amyotrophic Lateral Sclerosis (ALS) Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing prevalence of ALS globally
3.2.1.2. Advances in medical research and technology for ALS treatment
3.2.1.3. Growing healthcare expenditure and awareness
3.2.1.4. Rising geriatric population susceptible to neurological disorders
3.2.2. Restraints
3.2.2.1. High cost of ALS treatment options
3.2.2.2. Limited effectiveness of current therapies
3.2.2.3. Stringent regulatory requirements for drug approval
3.2.3. Opportunities
3.2.3.1. Research and development initiatives for novel therapies
3.2.3.2. Collaborations between pharmaceutical companies and research institutions
3.2.3.3. Technological advancements in diagnostic tools for early detection
3.2.4. Challenges
3.2.4.1. Ethical concerns related to experimental ALS therapies
3.2.4.2. Uneven access to ALS treatments across different regions
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies
5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis
6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis
7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview
7.1. Market Size & Forecast, 2019-2030
7.1.1. By Value (USD Billion)
7.2. Market Share and Forecast
7.2.1. By Type
7.2.1.1. Sporadic ALS (SALS)
7.2.1.2. Familial ALS (FALS)
7.2.2. By Treatment
7.2.2.1. Medication
7.2.2.2. Physical Therapy
7.2.2.3. Respiratory Therapy
7.2.2.4. Speech Therapy
7.2.2.5. Others
7.2.3. By End User
7.2.3.1. Specialty Centers
7.2.3.2. Research & Academic Institutes
7.2.3.3. Others
7.2.4. By Region
7.2.4.1. North America
7.2.4.2. Europe
7.2.4.3. Asia Pacific (APAC)
7.2.4.4. Latin America (LATAM)
7.2.4.5. Middle East and Africa (MEA)
8. North America Amyotrophic Lateral Sclerosis (ALS) Market
8.1. Market Size & Forecast, 2019-2030
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment
8.2.3. By End User
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. By Type
8.2.4.1.2. By Treatment
8.2.4.1.3. By End User
8.2.4.2. Canada
8.2.4.2.1. By Type
8.2.4.2.2. By Treatment
8.2.4.2.3. By End User
9. Europe Amyotrophic Lateral Sclerosis (ALS) Market
9.1. Market Size & Forecast, 2019-2030
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment
9.2.3. By End User
9.2.4. By Country
9.2.4.1. Germany
9.2.4.1.1. By Type
9.2.4.1.2. By Treatment
9.2.4.1.3. By End User
9.2.4.2. United Kingdom
9.2.4.2.1. By Type
9.2.4.2.2. By Treatment
9.2.4.2.3. By End User
9.2.4.3. Italy
9.2.4.3.1. By Type
9.2.4.3.2. By Treatment
9.2.4.3.3. By End User
9.2.4.4. France
9.2.4.4.1. By Type
9.2.4.4.2. By Treatment
9.2.4.4.3. By End User
9.2.4.5. Spain
9.2.4.5.1. By Type
9.2.4.5.2. By Treatment
9.2.4.5.3. By End User
9.2.4.6. Belgium
9.2.4.6.1. By Type
9.2.4.6.2. By Treatment
9.2.4.6.3. By End User
9.2.4.7. Russia
9.2.4.7.1. By Type
9.2.4.7.2. By Treatment
9.2.4.7.3. By End User
9.2.4.8. The Netherlands
9.2.4.8.1. By Type
9.2.4.8.2. By Treatment
9.2.4.8.3. By End User
9.2.4.9. Rest of Europe
9.2.4.9.1. By Type
9.2.4.9.2. By Treatment
9.2.4.9.3. By End User
10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market
10.1. Market Size & Forecast, 2019-2030
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Treatment
10.2.3. By End User
10.2.4. By Country
10.2.4.1. China
10.2.4.1.1. By Type
10.2.4.1.2. By Treatment
10.2.4.1.3. By End User
10.2.4.2. India
10.2.4.2.1. By Type
10.2.4.2.2. By Treatment
10.2.4.2.3. By End User
10.2.4.3. Japan
10.2.4.3.1. By Type
10.2.4.3.2. By Treatment
10.2.4.3.3. By End User
10.2.4.4. South Korea
10.2.4.4.1. By Type
10.2.4.4.2. By Treatment
10.2.4.4.3. By End User
10.2.4.5. Australia & New Zealand
10.2.4.5.1. By Type
10.2.4.5.2. By Treatment
10.2.4.5.3. By End User
10.2.4.6. Indonesia
10.2.4.6.1. By Type
10.2.4.6.2. By Treatment
10.2.4.6.3. By End User
10.2.4.7. Malaysia
10.2.4.7.1. By Type
10.2.4.7.2. By Treatment
10.2.4.7.3. By End User
10.2.4.8. Singapore
10.2.4.8.1. By Type
10.2.4.8.2. By Treatment
10.2.4.8.3. By End User
10.2.4.9. Vietnam
10.2.4.9.1. By Type
10.2.4.9.2. By Treatment
10.2.4.9.3. By End User
10.2.4.10. Rest of APAC
10.2.4.10.1. By Type
10.2.4.10.2. By Treatment
10.2.4.10.3. By End User
11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market
11.1. Market Size & Forecast, 2019-2030
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Treatment
11.2.3. By End User
11.2.4. By Country
11.2.4.1. Brazil
11.2.4.1.1. By Type
11.2.4.1.2. By Treatment
11.2.4.1.3. By End User
11.2.4.2. Mexico
11.2.4.2.1. By Type
11.2.4.2.2. By Treatment
11.2.4.2.3. By End User
11.2.4.3. Argentina
11.2.4.3.1. By Type
11.2.4.3.2. By Treatment
11.2.4.3.3. By End User
11.2.4.4. Peru
11.2.4.4.1. By Type
11.2.4.4.2. By Treatment
11.2.4.4.3. By End User
11.2.4.5. Rest of LATAM
11.2.4.5.1. By Type
11.2.4.5.2. By Treatment
11.2.4.5.3. By End User
12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market
12.1. Market Size & Forecast, 2019-2030
12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By Treatment
12.2.3. By End User
12.2.4. By Country
12.2.4.1. Saudi Arabia
12.2.4.1.1. By Type
12.2.4.1.2. By Treatment
12.2.4.1.3. By End User
12.2.4.2. UAE
12.2.4.2.1. By Type
12.2.4.2.2. By Treatment
12.2.4.2.3. By End User
12.2.4.3. Qatar
12.2.4.3.1. By Type
12.2.4.3.2. By Treatment
12.2.4.3.3. By End User
12.2.4.4. Kuwait
12.2.4.4.1. By Type
12.2.4.4.2. By Treatment
12.2.4.4.3. By End User
12.2.4.5. South Africa
12.2.4.5.1. By Type
12.2.4.5.2. By Treatment
12.2.4.5.3. By End User
12.2.4.6. Nigeria
12.2.4.6.1. By Type
12.2.4.6.2. By Treatment
12.2.4.6.3. By End User
12.2.4.7. Algeria
12.2.4.7.1. By Type
12.2.4.7.2. By Treatment
12.2.4.7.3. By End User
12.2.4.8. Rest of MEA
12.2.4.8.1. By Type
12.2.4.8.2. By Treatment
12.2.4.8.3. By End User
13. Competitive Landscape
13.1. List of Key Players and Their Offerings
13.2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
15.1. Mitsubishi Tanabe Pharma Corporation
15.2. Otsuka Pharmaceutical Co., Ltd
15.3. BrainStorm Therapeutics
15.4. Biogen Inc.
15.5. Corestem
15.6. AB Science
15.7. F.Hoffmann-La Roche AG
15.8. Biohaven Pharmaceutical
15.9. Sun Pharmaceutical
15.10. Ionis Pharmaceuticals, Inc.
15.11. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
17.1. Qualitative Research
17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
17.3.1. Secondary Research
17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable